X4 Pharmaceuticals

📍 Boston, United States🗓 Founded 2014👥 145 employees💰 Last funded Sep 2019
Biotechnology Research🌐 x4pharma.com
Website LinkedIn
We are a commercial-stage clinical biopharmaceutical company driven to improve the lives of people with rare diseases of the immune system and few to no treatment options. We have successfully developed mavorixafor, receiving FDA approval for XOLREMDI® (mavorixafor) in its first indication, and are currently executing our US launch. We are also advancing mavorixafor for additional rare disease patient populations, and expect to initiate a pivotal, global Phase 3 clinical trial in people with certain chronic neutropenic disorders. With a focus on CXCR4 and immune system biology, we continue to leverage our expertise both at our corporate headquarters in Boston, Massachusetts and at our research center of excellence in Vienna, Austria to further advance our patient-centric mission.
2
Total investors
1
Early stage
1
Mid stage
0
Late stage
2014
Founded

Investors

2 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
2
Frequently asked questions
Who invested in X4 Pharmaceuticals?
X4 Pharmaceuticals has 2 investors on record on gritt.io, including 1 early-stage backers, 1 mid-stage.
When did X4 Pharmaceuticals last raise funding?
The most recent investment in X4 Pharmaceuticals recorded on gritt.io was in September 2019.
When was X4 Pharmaceuticals founded?
X4 Pharmaceuticals was founded in 2014.
What industry is X4 Pharmaceuticals in?
X4 Pharmaceuticals operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is X4 Pharmaceuticals based?
X4 Pharmaceuticals is headquartered in Boston, United States.